biostudies-literatureWinter SSNCI NIH HHS585-589https://www.ebi.ac.uk/biostudies/studies/S-EPMC8791581biostudies-literatureUnknown6(2)Immunotherapies directed against B-cell surface markers have been a common developmental strategy to treat B-cell malignancies. The immunoglobulin heavy chain surrogate light chain (SLC), comprising the VpreB1 (CD179a) and Lamda5 (CD179b) subunits, is expressed on pro- and pre-B cells, where it governs pre-B-cell receptor (BCR)-mediated autonomous survival signaling. We hypothesized that the pre-BCR might merit the development of targeted immunotherapies to decouple "autonomous" signaling in B-lineage acute lymphoblastic leukemia (B-ALL). We used the Children's Oncology Group (COG) minimal residual disease (MRD) flow panel to assess pre-BCR expression in 36 primary patient samples accrued to COG standard- and high-risk B-ALL studies through AALL03B1. We also assessed CD179a expression in 1Blood advancesVpreB surrogate light chain expression in B-lineage ALL: a report from the Children's Oncology Group.PMC8791581P30 CA021765U10 CA180886R35 CA197695U10 CA180899U24 CA196173Qu CWilson BSCarroll AJMullighan CGSimeona NWinter SSHeerema NAGheorghe GMcCaustland AWood BLfalseVpreB surrogate light chain expression in B-lineage ALL: a report from the Children's Oncology Group.Immunotherapies directed against B-cell surface markers have been a common developmental strategy to treat B-cell malignancies. The immunoglobulin heavy chain surrogate light chain (SLC), comprising the VpreB1 (CD179a) and Lamda5 (CD179b) subunits, is expressed on pro- and pre-B cells, where it governs pre-B-cell receptor (BCR)-mediated autonomous survival signaling. We hypothesized that the pre-BCR might merit the development of targeted immunotherapies to decouple "autonomous" signaling in B-lineage acute lymphoblastic leukemia (B-ALL). We used the Children's Oncology Group (COG) minimal residual disease (MRD) flow panel to assess pre-BCR expression in 36 primary patient samples accrued to COG standard- and high-risk B-ALL studies through AALL03B1. We also assessed CD179a expression in 12022-01-01T00:00:00Z2022 Jan2026-05-28T23:33:44.508Z2022-02-11T15:57:22.864ZS-EPMC87915813466289110.1182/bloodadvances.2021005245